We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 01, 2020

Durvalumab Alone and Durvalumab Plus Tremelimumab vs Chemotherapy in Patients With Metastatic Urothelial Carcinoma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Durvalumab Alone and Durvalumab Plus Tremelimumab Versus Chemotherapy in Previously Untreated Patients With Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE): A Randomised, Open-Label, Multicentre, Phase 3 Trial
Lancet Oncol 2020 Sep 21;[EPub Ahead of Print], T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, DP Petrylak, O Ogawa, SH Park, JL Lee, U De Giorgi, M Bögemann, A Bamias, BJ Eigl, H Gurney, SD Mukherjee, Y Fradet, I Skoneczna, M Tsiatas, A Novikov, C Suárez, AP Fay, I Duran, A Necchi, S Wildsmith, P He, N Angra, AK Gupta, W Levin, J Bellmunt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading